News Image

NASDAQ:NBIX is probably undervalued for the fundamentals it is displaying.

By Mill Chart

Last update: Mar 14, 2024

Uncover the potential of NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) as our stock screener's choice for an undervalued stock. NASDAQ:NBIX maintains a strong financial position and offers an appealing valuation. We'll delve into the specifics below.

Analyzing Valuation Metrics

ChartMill provides a Valuation Rating to every stock, ranging from 0 to 10. This rating assesses various valuation aspects, comparing price to earnings and cash flows, while considering factors like profitability and growth. NASDAQ:NBIX boasts a 7 out of 10:

  • Based on the Price/Earnings ratio, NBIX is valued cheaply inside the industry as 95.12% of the companies are valued more expensively.
  • Based on the Price/Forward Earnings ratio, NBIX is valued cheaper than 95.45% of the companies in the same industry.
  • Based on the Enterprise Value to EBITDA ratio, NBIX is valued cheaper than 94.95% of the companies in the same industry.
  • NBIX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. NBIX is cheaper than 95.12% of the companies in the same industry.
  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • NBIX has an outstanding profitability rating, which may justify a higher PE ratio.
  • NBIX's earnings are expected to grow with 53.13% in the coming years. This may justify a more expensive valuation.

Profitability Examination for NASDAQ:NBIX

ChartMill utilizes a Profitability Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of profitability ratios and margins, both in absolute terms and in comparison to industry peers. NASDAQ:NBIX has earned a 9 out of 10:

  • The Return On Assets of NBIX (7.68%) is better than 96.97% of its industry peers.
  • NBIX has a better Return On Equity (11.19%) than 96.63% of its industry peers.
  • NBIX's Return On Invested Capital of 11.21% is amongst the best of the industry. NBIX outperforms 96.80% of its industry peers.
  • The last Return On Invested Capital (11.21%) for NBIX is above the 3 year average (9.89%), which is a sign of increasing profitability.
  • NBIX has a Profit Margin of 13.23%. This is amongst the best in the industry. NBIX outperforms 96.63% of its industry peers.
  • In the last couple of years the Profit Margin of NBIX has grown nicely.
  • With an excellent Operating Margin value of 20.92%, NBIX belongs to the best of the industry, outperforming 97.14% of the companies in the same industry.
  • NBIX's Operating Margin has improved in the last couple of years.
  • With an excellent Gross Margin value of 97.90%, NBIX belongs to the best of the industry, outperforming 97.81% of the companies in the same industry.

Health Assessment of NASDAQ:NBIX

ChartMill employs its own Health Rating for stock assessment. This rating, ranging from 0 to 10, is calculated by examining various liquidity and solvency ratios. In the case of NASDAQ:NBIX, the assigned 7 reflects its health status:

  • An Altman-Z score of 9.57 indicates that NBIX is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 9.57, NBIX belongs to the top of the industry, outperforming 84.85% of the companies in the same industry.
  • NBIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
  • A Current Ratio of 2.45 indicates that NBIX has no problem at all paying its short term obligations.
  • NBIX has a Quick Ratio of 2.40. This indicates that NBIX is financially healthy and has no problem in meeting its short term obligations.

Analyzing Growth Metrics

To evaluate a stock's growth potential, ChartMill utilizes a Growth Rating on a scale of 0 to 10. This comprehensive assessment considers various growth aspects, including historical and estimated EPS and revenue growth. NASDAQ:NBIX has achieved a 9 out of 10:

  • The Earnings Per Share has grown by an impressive 58.17% over the past year.
  • The Earnings Per Share has been growing by 70.09% on average over the past years. This is a very strong growth
  • Looking at the last year, NBIX shows a very strong growth in Revenue. The Revenue has grown by 26.76%.
  • NBIX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 33.13% yearly.
  • Based on estimates for the next years, NBIX will show a very strong growth in Earnings Per Share. The EPS will grow by 42.64% on average per year.
  • Based on estimates for the next years, NBIX will show a quite strong growth in Revenue. The Revenue will grow by 13.87% on average per year.

Our Decent Value screener lists more Decent Value stocks and is updated daily.

Check the latest full fundamental report of NBIX for a complete fundamental analysis.

Disclaimer

This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.

Back

NEUROCRINE BIOSCIENCES INC

NASDAQ:NBIX (5/17/2024, 7:15:36 PM)

After market: 142.29 0 (0%)

142.29

+0.38 (+0.27%)

NBIX News

News Image3 days ago - Market News VideoInteresting NBIX Put And Call Options For July 19th
News Image3 days ago - Market News VideoNeurocrine Biosciences Moves Up In Market Cap Rank, Passing Pool
News Image6 days ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024

- CAHtalyst™ Phase 3 Baseline Characteristics Highlight Limitations of Current CAH Treatment Paradigm in Children, Adolescents and Adults - Phase 2 Study for...

News Image11 days ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present CAHtalyst™ Adult Phase 3 clinical study baseline...

News Image11 days ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the safety,...

News Image12 days ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the...

News Image12 days ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the BofA Securities 2024 Health Care Conference at 11:20 a.m. Pacific Time (2:20...

News Image14 days ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today renewed its commitment to increasing awareness and advancing care for people living with TD...

News Image16 days ago - Investor's Business DailyNvidia Leads Five Stocks Near Buy Points As Market Rally Picks Up Steam

The market rally appears to be picking up steam.

News Image16 days ago - Investor's Business DailyA Week Of Fast-Moving Stocks Ahead: Disney, Toyota, Ferrari, Constellation

Earnings season moves into final innings, some fast-moving names led by Disney, Ferrari and Constellation report.

News Image16 days ago - Investor's Business DailyStock Market Rallies On Fed, Jobs Report, Apple: Weekly Review

The Nasdaq regained its 50-day line Friday. The other indexes hit resistance.

News Image16 days ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today presented the CAHtalyst™ Pediatric Phase 3 clinical study baseline characteristics data for...

NBIX Links
Follow us for more